Another TKI (lenvatinib) can decrease tumor vascular permeability and inhibit tumor neovessel maturation and assembly through targeting VEGFR1–3, fibroblast growth factor receptor (FGFR)1–4, PDGFR-α, c-Kit protein, and RET protein. Here, RET is linked to neoplasm.